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Abstract
Aim: To investigate the effectiveness and safety of a 
symbiotic mixture in preventing recurrence of constipation-
related abdominal pain in patients with uncomplicated 
diverticular disease of the colon. Methods: Forty-six 
consecutive patients (10 men, 36 women, mean age 
62.5 years, range 49 to 77 years), previously affected by 
symptomatic uncomplicated diverticular disease of the colon, 
were enrolled in a 6-month follow-up study in a prospective, 
randomized, open-label study. The following symptoms 
were assessed at entry and through follow-up by using a 
quantitative scale: constipation, diarrhoea and abdominal 
pain. After recruitment, the patients were assigned to the 
following treatment: SCM-III symbiotic mixture, 10ml 
three times a day. The colonization of ingested Lactobacillus 
acidophilus 145 and Bifi dobacterium spp. 420 was assessed 
by specie-specifi c PCR. Forty-fi ve patients completed the 
study (97%). Results: Thirty-one patients (68%) were still 
symptom free after the 6th month of treatment. Treatment 
with SCM-III was regarded as “effective” or “very effective” 
in more than 78% of the patients altogether (p<0.01 vs 
baseline values). The microbiological study showed that, as 
compared to baseline values, SCM-III enabled a signifi cant 
increase of the lactobacilli and bifi dobacteria counting and a 
trend decrease of clostridia. Genomic analysis confi rmed the 
survivability of the ingested strain as long as treatment was 
given. Conclusions: The present symbiotic mixture seems 
to be effective in preventing recurrence of symptomatic 
uncomplicated diverticular disease of the colon, especially 
in those patients with constipation-predominant features.
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Introduction  
Diverticular disease of the colon is very common in 
developed countries and its prevalence increases with 
age and up to an estimated 20% of patients may manifest 
clinically-relevant illness in their lives [1]. The treatment 
of uncomplicated diverticulitis (characterized by lower 
abdominal pain, fever, and bowel movement alterations) 
is generally non surgical whereas the latter option is 
usually required when serious complications supervene. 
In uncomplicated diverticular disease, treatment is aimed 
at relieving symptoms which may remarkably affect the 
quality of life of these patients requiring poorly absorbable 
antibiotics or anti-infl ammatory drugs [2]. Nonetheless, 
despite the high prevalence of this disease, literature data 
on the treatment for maintaining remission in symptomatic 
diverticular disease is still a matter of debate. Stasis of 
luminal contents may occur within colonic diverticula, 
and it is probably associated with changes in the spectrum 
of intestinal microfl ora although such assumption has not 
been fully demonstrated yet. However, it is likely that faecal 
stasis and dysbiosis may trigger the formation and topical 
release of abnormal metabolites eventually causing those 
inflammatory/functional changes leading to abdominal 
symptoms. A recent study has showed that only less than 
60% of patients using rifaximin for tentative maintenance 
treatment were symptom free at the 12th month of follow 
up [3]. On the other hand, concomitant constipation might 
represent a causative factor in the occurrence of symptomatic 
fl are up. Dietary changes and disaccharides are among the 
most common prescriptions in such cases but their effective 
clinical benefi t is not entirely established. 
Given the complex interplay between the gut ecosystem 
and gastrointestinal function, the tentative manipulation of 
the gut fl ora through viable bacteria administration has in 
recent times being proposed as a further rational therapeutic 
option. Probiotics have been defined as viable micro-
organisms which, when ingested, might exert benefi cial 
effects in the prevention and treatment of a number of specifi c 
pathologic disorders [4-8]. A further possibility in microfl ora 
management procedures is the use of symbiotics in which the 
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live microbial species are combined with specifi c substrates 
(prebiotics) for growth and improved survival [9, 10] and 
such an approach might be an amenable tool in the weaponry 
of treating this disease. The rationale for using probiotics 
in the treatment of diverticular disease is likely to be due 
to their reported production of antimicrobials, competitive 
metabolic interactions with pro-infl ammatory organisms, 
and inhibition of adherence and translocations of pathogens. 
They may also infl uence mucosal defence at the levels of 
immune and epithelial function, such as decreasing several 
pro-infl ammatory cytokines. Moreover, Fric et al [11] have 
recently showed the effectiveness of probiotics in treating 
uncomplicated acute diverticulitis of the colon. About 60% 
of patients suffering from a previous attack of diverticulitis 
and not taking any medication in preventing recurrence of 
symptoms are symptomatic within 1 year. However, there 
is a large number of patients with diverticular disease, 
especially if with underlying constipation, who regularly 
undergo uncomplicated symptomatic phases requiring 
drug treatment. We have recently shown in experimental 
and clinical settings that a novel symbiotic could exert 
a signifi cantly benefi cial effect on gut translocation and 
local and systemic infl ammatory and microbial metabolic 
parameters [12-14]. 
In light of these data, we conducted a prospective study 
evaluating the effectiveness and tolerability of a symbiotic 
mixture preventing recurrence of symptomatic diverticular 
disease of the colon and, in particular, in those patients 
presenting a constipation-predominant pattern. We also 
checked the survivability of ingested bacteria by genomic 
tools which have been highlighted as possible gold-standard 
in the fi eld, recently pointed out in a detailed review by 
Yadav et al [15]. 
Material and methods 
From July 2006 to September 2007, a prospective, open-
label study was conducted on 46 consecutive patients (10 men, 
36 women, mean age 67.5 yrs, range 39 to 77 yrs) presenting 
with a history of recurring constipation-predominant 
symptomatic uncomplicated diverticular disease of the colon 
(average 1.2 episodes/month). Diagnosis of symptomatic 
uncomplicated diverticular disease of the colon was defi ned 
as nonspecifi c abdominal complaints (intensity over 3 on a 
VAS evaluation) in patients with diverticula of the colon, 
without any systemic sign or symptom of infl ammation, 
according to well-defi ned criteria and requiring medical 
treatment (either by self-administration or by health 
professionals) such as antispasmodic drugs and/or painkillers 
and/or oral or enema laxatives. In particular, spasmolytics 
were used in 38 (82.6%), non absorbable antibiotics in 29 
(63%), fi bers in 6 (13%). Twenty-one out of 46 (45.6%) 
patients referred had a history of diverticulitis. Diagnosis 
of diverticular disease was established by colonoscopy or 
bowel enema in all patients. Diverticula were localized in 
overall colon in 3 patients (6.5%), overall leftsided colon in 
17 patients (36.9%) and only in the sigma in 25 (54.3%).
Criteria for exclusion from the study were an active or 
recent peptic ulcer, chronic renal insuffi ciency and presence 
of ongoing or past major diverticulitis complications. 
Moreover, all systemic and non-absorbable antibiotics and 
antifungal medications, suppositories, herbal supplements 
and food containing live active cultures were considered 
as exclusion criteria. Patients were also given a dietary 
questionnaire in order to detect any major changes during 
the study period.
Study design
The study period began with the baseline evaluation 
(day 0) and ended with the fi nal visit, on the 6th month. 
Stool samples were collected at 0, 1, 3 and 6 months. We 
assessed the following symptoms in all enrolled patients: 
(1) constipation, (2) diarrhoea and (3) abdominal pain. The 
intensity of the symptoms was scored on a quantitative scale 
of 0 to 3 according to worsening of symptoms: 0: absence; 
1 - slight; 2- mild/moderate; 3 - severe. All patients were 
asymptomatic at the time of enrolment and showed a score 
of 0 in all parameters evaluated. Patients were also instructed 
to rate the below-mentioned parameters on diary cards. 
The overall clinical improvement (OCI) as compared to 
their status in the past three months was assessed at each 
visit using a four-point scale (1: very effective, 2: effective; 
3: unchanged, 4: worsened). All patients were assigned 
to the following treatment schedule: SCM-III 10 ml t.i.d. 
(Microfl orana-F, Named, Lesmo, Italy. Composition for 
100 ml: L. acidophilus strain 145 1.25 x 106, L. helveticus 
ATC 15009 1.3 x 109, Bifi dobacterium spp. 420 4.95 x 
109 in a phytoextracts-enriched medium. This consists of: 
urtica dioica, ribes nigrum, vaccinium myrtillus, taraxacum 
officinalis leaves and roots, daucus carota, equinacea 
purpurea leaves and roots in the amount of 82g/100ml). 
Specifi c genomic primers for L. acidophilus 145 and 
Bifi dobacterium spp 420 contained in the mixture were 
developed to identify the specifi c strain survival along the 
gastrointestinal tract. Patients were enrolled in a 6-month 
follow-up study taking into account the symptoms by using 
a quantitative scale. All patients were asymptomatic at the 
time of enrolment and showed a score of 0 in all parameters 
evaluated. 
Clinical check ups were planned at the end of the 1st, 3rd 
and 6th month of treatment. Measurements of acceptability 
and tolerability, the presence of possible side effects and 
patients’ compliance were recorded also and a detailed 
form was provided to patients and physicians. Clinical 
examination and biochemical tests were made available to 
all patients in each possible case of querying side effects or a 
supervening complication related to the underlying disease. 
The intention-to-treat analysis included all patients and 95% 
confi dence intervals (CI) were provided. 
Stool microfl ora analysis
Stool specimens were collected in pre-weighed collection 
tubes containing liquid phosphate buffered saline + 1% 
gelatin medium. Collection tubes were frozen until used. 
A stool sample of approximately 2-5 g was placed in the 
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collection tube and then dispersed in the transport media. 
The tube was sealed, immediately agitated until the stool 
and liquid were mixed thoroughly, and then refrigerated. The 
stool sample was weighed, and cultured within 72 hours of 
collection. Determination of bacterial fl ora was carried out as 
reported by Mitsuoka et al [16]. Briefl y, 9ml of a diluent was 
added to 1g of the faecal sample, the mixture was vigorously 
shaken and tenfold serial dilutions of the suspension were 
prepared. Each dilution was set in aliquots of 0.05ml onto 
agar plates of media which was appropriate for the target 
organisms as follows. The following organisms were counted 
on selective media to the genus level: Bifi dobacterium 
– Reinforced Clostridial agar plus nalidixic acid (20 mg/
L), polymixin B (8.5 mg/mL), kanamycin (12.5 mg/mL), 
iodoacetic acid (12 mg/L), and 2,3,5 triphenyl tetrazolium 
chloride (25 mg/mL); Enterococcus – KF Streptococcal agar; 
Clostridium - Clostrisel agar. The quantitative culture was 
performed by plating 100 µl of diluted stool specimen onto 
each agar medium. The plate surfaces were allowed to dry for 
15 minutes and then placed in an appropriate environment. 
Lactobacilli, bifidobacteria, and clostridia plates were 
incubated in an anaerobic chamber at 37º C for a minimum 
of 4 days. Enterococci plates were incubated for 48 hours in 
a 5% CO2 atmosphere at 37º C. Bacterial identifi cation was 
assessed upon the morphology of the colonies, microscopic 
examination of Gram-stained slides, tests for growth under 
aerobic conditions and appropriate biochemical tests. For 
all organisms, total colony counts were reported as less than 
detectable (<102) or detectable ( ≥102). Using these criteria, 
this methodology detected at least 102 colony forming units 
(CFU)/g stool. 
Extraction of DNA from faecal samples 
Each collected faecal sample was stored at -80°C until 
DNA was extracted. Faecal samples (20 mg) were washed 
3 times in 1.0 mL of phosphate buffered solution and 
centrifuged at 14 000g. Faecal pellets were resuspended 
in 450 μL of extraction buffer (100 mM Tris-HCl, 40 mM 
EDTA, pH 9.0) and 50 μL of 10% SDS. Glass beads (300 
mg; diameter, 0.1 mm) and 500 μL of buffer-saturated phenol 
were added to the suspension and the mixture was vigorously 
vortexed for 30 seconds. Then, 50 µl of cell lysing solution 
(60 mg/ml of lysozyme, 1 mg/ml of N-acetylmuramidase) 
was added to the bead solution to assure effi cient degradation 
of bacterial cell walls. After centrifugation at 14 000g for 5 
minutes, 400 μL of supernatant was extracted with phenol-
chloroform and 250 μL of the supernatant was precipitated 
with isopropanol. DNA was purifi ed using a High Pure 
Polymerase Chain Reaction (PCR) Template Preparation 
kit (Roche, Basel, Switzerland) and suspended in 200 μL of 
TE buffer and DNA was fi nally extracted. The DNA yields 
from faecal samples was 211 ± 55 ng. 
Species-specifi c quantitative real-time PCR detection 
of L. acidophilus and Bifi dobacterium colonization 
For the selection of primer and probe sequences, the 16S-
23S intergenic spacer regions of the different Lactobacillus 
species was retrieved from the GenBank, EMBL, and 
DDBJ databases. Specifi c sequences were identifi ed to 
design primers and probes for L. acidophilus and the primer 
and probe were tested for specifi city using the basic local 
alignment search tool which proved to fulfi ll the related 
criteria (F GAA AGA GCC CAA ACC AAG TGA TT 
R_acid_IS CTT CCC AGA TAA TTC AAC TAT CGC TTA 
P_acid_IS TAC CAC TTT GCA GTC CTA CA). The 5’ 
reporter dye VIC and the 3’ quencher NFQ-MGB served as 
probes for the detection of the genus  L. acidophilus 145.
Moreover, TaqMan minor groove binding probes were also 
used to further increase specifi city and sensitivity. 
Bifidobacterium spp. colony morphologies from 
each fecal sample were randomly selected from each 
bifi dobacteria culture plate for PCR analysis. Part of the 
colony was suspended in 20 µL of sterile distilled water 
and 4µL of this suspension served as a template for PCR. 
Amplifi cation of the template DNA was carried out in 45 
µL of PCR Supermix and 0.5 µL (100 pmol/µlLl) of each 
of the two primers. Bifi dobacterium spp. 420-spp. primers 
were used for PCR amplifi cation. Primer sequences are as 
follows: Bfl act2 (5’ - GTGGAGACACGGTTTCCC-3’) 
and Bflact5 (5’ -CACACCACACAATCCAATAC -3’). 
Amplifi cation of DNA was performed in a thermal cycler 
programmed as such: 10 min at 95°C and 30 cycles of 30 
sec at 95°C, 1 min at 58°C, 4 min at 72°C, followed by 
7 min at 72°C. Amplicons were identifi ed by ethidium 
bromide staining following electrophoresis in 1.2% TAE 
agarose gels. Bifi dobacterium spp. 420 specifi c colonies 
were expected to yield a single band of 680 bp, in contrast 
to non- Bifi dobacterium spp. 420 samples which did not 
yield any amplicons. When no amplicons were present after 
the Bifi dobacterium spp. 420-specifi c PCR, the presence of 
template bacterial DNA was confi rmed to rule out a false 
negative. For this PCR, amplifi cation of template DNA was 
performed as described above and directed by 16S rRNA 
primers under the following cycling conditions: 5 min at 
94°C and 35 cycles of 15 sec at 94°C, 30 sec at 57°C, 90 
sec at 72°C, followed by 10 min at 72°C. Colonization was 
defi ned as the PCR-based detection of Bifi dobacterium spp. 
420 in any of one or more of the fi ve selected unique colony 
morphotypes. The relative amounts of the different bacterial 
species in faecal samples were calculated after correction for 
differences in the amplifi cation effi ciencies of the PCR.
Statistical analysis
Signifi cance was established by analysis of variance 
and the level of signifi cance was determined by employing 
a Duncan’s multiple-range test. Data were expressed in the 
text as means (SD) and a probability value of <0.05 was set 
as indicating that a statistically signifi cant difference existed 
between experimental groups. The scores of effi cacy and the 
intensity and frequency of the symptoms were evaluated as 
compared to baseline values by Mann-Whitney-Wilcoxon 
rank test. 
Results
No evident clinical (diarrhoea, abdominal pain, nausea) 
or biochemical adverse side effects were recorded nor any 
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diverticulitis sign was recorded throughout the study period. 
Compliance was satisfactory as all patients took more than 
98% of the symbiotic prescribed. About 9% of patients 
(4/46) reported a poor palatability of the symbiotic. Forty-
fi ve patients completed the study (97.8%): 1 patient was 
withdrawn from the study for protocol violation (the use of 
a systemic antibiotic for extra intestinal disease). Thirty-one 
patients (31/45 patients: 68.8 %) were still symptom free 
after the 6th month of treatment (p<0.05). Treatment with 
SCM-III was regarded as “effective” or “very effective” 
in 77.2% of the patients altogether (p<0.01 vs baseline 
values, data not shown). No worsening was reported as a 
fi nal assessment at the end of the study period and about 
6% (3/45) reported a “not effective” result. The total number 
of constipation-related abdominal pain expected (intensity 
≥2) showed a signifi cant decrease with an overall reduction 
of two-third of expected episodes which was maintained 
throughout the 6-month observation period (p<0.01, Fig. 
1). At a further analysis, it appeared that two-thirds of the 
patients reporting episodes of mild discomfort at entry 
(intensity <2, 10/13 patients) had improved or normalized 
their bowel habits (data not shown).
Fig 1. Total number of episodes of constipation-related abdominal 
pain (intensity ≥2). Effect of SCM-III.
The microbiological study showed that, as compared 
to baseline values, SCM-III enabled a signifi cant increase 
of total anaerobes and in particular of lactobacilli and 
bifi dobacteria together with a trend decrease of clostridia 
counting (p<0.05, Table I). Streptococci counting remained 
unchanged. Such effect occurred in all patients and was 
not related to the baseline counting of each strain nor to 
the clinical variables examined (duration of the disease, 
past antibiotics treatment, age, gender, main dietary style). 
Genomic analysis confi rmed the signifi cant survivability 
of ingested L. acidophilus and Bifi dobacterium contained 
in the symbiotic mixture. In particular, at baseline no stool 
samples contained L. acidophilus 145 nor Bifi dobacterium 
spp. 420. However, both bacteria were recovered from the 
stools of patients along the symbiotic supplementation period 
and peaking at the 3rd month observation (Fig. 2, p<0.001 
vs baseline).
Finally, 12 patients positive in both strains at 6-month 
observation discontinued the treatment and were subjected 
Table I. Faecal  fl ora assessment in symptomatic diverticular disease: 
effects of SCM-III
Bacterial species
(log no./g wet feces)
(healthy control)
Baseline SCM-III
Total aerobes 8.2 ± 0.22 8.18 ± 0.34
Total anaerobes 10.1 ± 0.12 10.8 ± 0.10*
Lactobacillus 7. 1 ± 0.11 8. 4 ± 0.09*
Bifi dobacterium 9.3 ± 0.34 10.1 ± 0.22*
Enterococcus 6. 2 ± 0.21 6. 3 ± 0.33
Clostridium 8. 5 ± 0.16 8. 1 ± 0.27
*p < 0.05
Fig 2. PCR detection of concomitant L. acidophilus 145 and 
Bifi dobacterium 420 colonization.
to follow up. Genomic analysis revealed that already after 
two weeks of the discontinuation of the administration of 
SCM-III, both the species strains were no longer detected. 
Discussion
The gastrointestinal tract is a complex microbial 
ecosystem, comprised of several hundred species of bacteria 
at a concentration of more than 1011 bacteria per gram of 
contents. These microbes have a potent infl uence on host 
health and a delicate equilibrium exists between organisms 
believed to benefi t the host and those that may be detrimental 
[17]. Accordingly, tentative gut fl ora manipulation through 
probiotics offers an ideal theoretical, albeit still cumbersome 
to evaluate, approach to gastrointestinal disease and gut-
related systemic illnesses. The symbiotic mixture we used in 
this study seems to be effective in preventing recurrence of 
symptomatic diverticular disease of the colon, expecially in 
those patients with constipation-predominant features. This 
specifi c subset of patients was chosen when considering the 
prokinetic-like properties exerted by this symbiotic in an 
experimental setting [18]. As a matter of fact, the majority of 
patients who were symptom-free at the entry into the study 
remained asymptomatic under SCM-III treatment while 
those who had minor discomfort did not experience any 
worsening while reporting an improvement/normalization 
of their bowel habits. 
Moreover, we have recently shown that this symbiotic 
is able to benefi cially modify the gut fl ora and its metabolic 
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activity in patients with liver cirrhosis [13] as well as to lower 
ammonia, benzodiazepine-like substances and endotoxin in 
this complex clinical setting [19], the latter being of some 
potential interest also in the triggering of severe infl ammatory 
changes of complicated diverticulitis [20].  
Moreover the PCR-based genomic approach employed 
in the present study confi rmed the effective colonization of 
the symbiotic mixture through a signifi cant survival of its 
two main probiotic strains in most but not all patients. In 
the present study the possible interference of small intestinal 
bacterial overgrowth which has been shown by Tursi et al 
[21] to be a very frequent associated phenomenon in this 
clinical set up was not assessed.
Taken altogether and with the limitation of a study 
addressing a rather heterogeneous population, it would 
appear that SCM-III exerts a signifi cant benefi cial effect in 
this condition and, namely, in those patients presenting with 
diverticular disease and constipation-related abdominal pain. 
These data fi nally suggest that treatment with balanced and 
viable symbiotic compounds may be a valuable and a likely 
preferable therapeutic option than repeat antibiotic treatment 
alone. Such a schedule should ideally be administered 
in a cyclic/subcontinuous regimen when considering the 
temporary effi cacy on the modifi cation of the faecal fl ora 
[22, 23] as also shown by genomic tools in our study. Indeed, 
cyclic probiotic administration for 10-15 days is able to 
maintain intestinal colonization for a further 15-20 days 
without any decreasing in bacterial concentration [19, 24]. 
On the other hand, long-term or repeat antibiotic treatment 
in the asymptomatic phase, and not specifi cally required 
for complicated diverticulitis, may increase also bacterial 
resistance, when used alone, having no prokinetic or sound 
microecological rationale in this setting. Moreover, it is 
known that bacterial re-colonization may take up to two 
weeks [25]. 
The optimal therapeutic regimen remains to be 
established using symbiotics and intertwining with anti-
infl ammatory drugs as suggested by Tursi et al [26-28] 
which may exert further specifi c intracellular benefi t at the 
mucosal level [29]. 
Conclusion
The present symbiotic mixture seems to be effective in 
preventing recurrence of symptomatic diverticular disease 
of the colon, especially in those patients with constipation-
predominant features while positively altering the gut 
fl ora.
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